This undated image provided by Supernus Pharmaceuticals in April 2021 shows bottles for different dosages of the drug Qelbree. On Friday, April 2, 2021, the U.S. Food and Drug Administration approved the medication for treating attention deficit hyperactivity disorder in children ages six through 17. (Supernus Pharmaceuticals via AP) health
FDA OKs first new ADHD drug in over a decade for children Today 05:47 am JST Today | 06:48 am JST WASHINGTON
U.S. regulators have approved the first new drug in over a decade for children with ADHD, which causes inattention, hyperactivity and impulsivity.
The Food and Drug Administration OK’d Qelbree (KELL’-bree) for treating attention deficit hyperactivity disorder in children ages 6 to 17. It comes as a capsule that’s taken daily.
Linda A. Johnson
U.S. regulators have approved the first new drug in over a decade for children with ADHD, which causes inattention, hyperactivity and impulsivity.
The Food and Drug Administration late Friday OK’d Qelbree (KELL’-bree) for treating attention deficit hyperactivity disorder in children ages 6 to 17. It comes as a capsule that’s taken daily.
Unlike nearly all other ADHD medicines, Qelbree is not a stimulant or a controlled substance, making it harder to abuse than older drugs. That’s been a problem with earlier ADHD treatments like Ritalin, nearly all of which contain the stimulants amphetamine or methylphenidate.